SGD Pharma is expanding its pharmaceutical glass packaging portfolio with new molded and tubular vial solutions aimed at drug developers working with high-value and increasingly sensitive therapies. Among the products being at CHPI Milan is MySterinity Nasal, a range of molded Type I glass vials designed for nasal drug delivery. SGD Pharma is positioning the range for applications where higher microbiological standards are required, including biologic-based therapies, central nervous system treatments and vaccines.

The U-Save nasal vials can be supplied pre-washed, depyrogenated or sterilized, giving pharmaceutical manufacturers flexibility in how they integrate the containers into their manufacturing processes. The company says the approach is intended to combine quality and safety requirements with improvements in total cost of ownership.

SGD Pharma is also moving further into ready-to-use (RTU) tubular vials for sensitive parenteral medicines. The new vials will be supplied washed, depyrogenated and sterilized for pharmaceutical companies operating aseptic fill-finish processes. The RTU range is intended to give customers a single source for their Type I RTU vial requirements while reducing the processing steps required before fill-finish. SGD Pharma also expects the offering to provide shorter delivery times and potential total-cost-of-ownership benefits.

Production will take place at SGD Pharma’s Felino facility in Italy, which operates in an ISO 5 environment. The site became part of SGD Pharma following its acquisition of Alphial, a move that has broadened the company’s capabilities in tubular glass packaging.

“One year after the acquisition of Alphial, SGD Pharma is well positioned to address the evolving challenges of the pharmaceutical industry,” says Olivier Rousseau, CEO of SGD Pharma. He added that sustainability considerations are being incorporated into the development of the company’s new products and services.

Alongside the vial launches, SGD Pharma is introducing MySealian, a GMP-compliant subcontracting service that allows pharmaceutical companies, glass manufacturers and OEMs to access its Sealian internal vial treatment without investing in their own treatment infrastructure. Sealian creates a protective barrier on the internal glass surface. According to SGD Pharma, the treatment improves the hydrophobic properties of the vial, which can help reduce the tendency of high-viscosity drug formulations to adhere to the glass. That can be particularly relevant for sensitive or high-value therapies, where product visibility during inspection and minimizing residual product can have practical and economic implications. The company will also offer Sealian treatment for its new tubular vial range, extending the technology beyond its existing molded-glass applications.

The expansion reflects SGD Pharma’s broader effort to build a portfolio spanning both molded and tubular pharmaceutical glass rather than focusing on a single container technology.

SGD Pharma will present the expanded portfolio at booth 11F17 during CPHI Milan. The company says its focus will be on helping pharmaceutical manufacturers address the quality, processing and supply-chain requirements associated with increasingly complex drug products.

Visit www.sgd-pharma.com for more information.